<DOC>
	<DOCNO>NCT00140725</DOCNO>
	<brief_summary>This single-centre prospective randomise study compare virological histological response HBV infection lamivudine combination interferon versus lamivudine alone .</brief_summary>
	<brief_title>Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus ( HBV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criterion : Untreated chronic hepatitis B patient evidence HBV replication document serum HNVDNA positive within 3 month prior entry serum HBeAg positive screening . Documented presence abnormal alanine aminotransferase ( ALT ) ( 1.3 5X upper limit normal ( ULN ) ) within 1 month prior entry sign compensate liver disease . Exclusion criterion : Patients cause liver disease chronic hepatitis B evidence history decompensated liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>HBeAg-positive</keyword>
	<keyword>chronic</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>lamivudine</keyword>
	<keyword>seroconversion</keyword>
	<keyword>Chronic Hepatitis B</keyword>
</DOC>